Now available: Issue 12 of the RESILIA Tissue Insider
July 2025
Issue 12
In this issue, we report how RESILIA tissue valves are performing at 8 years in the COMMENCE trial and showcase real-world studies on these valves. We also explore the history of bioprosthetic valve innovation in the latest of our new feature articles. Other highlights include:
- Interview: Prof. Borger and Dr Kaneko joined us to dissect the 8-year outcomes of the COMMENCE trial
- Interview: Professor Diana Reser shared her remarkable journey to become Switzerland’s first female professor of cardiac surgery
- Cost-effectiveness studies of aortic RESILIA tissue valves: exploratory model for Spain and meta-analysis with clinical outcomes
Starting with the first bioprosthetic valve implantations in patients in 1965, Edwards Lifesciences has worked tirelessly towards creating a durable and functional bioprosthetic valve for patients. This journey continues with the development of RESILIA tissue valves: with novel anticalcification techniques for potentially longer durability, and features that facilitate future valve-in-valve technology.
In this issue, we present the latest research in the RESILIA tissue portfolio, including the longest COMMENCE trial follow-up to date, which reports on patients with RESILIA tissue valves in the aortic position. We also caught up with Dr Tsuyoshi Kaneko and Professor Michael Borger at The Heart Valve Society Annual Meeting to hear their thoughts on these results.
Discover more on RESILIA tissue through the current and past issues below.
Previous issue
March 2025
Issue 11
In this issue, we introduce our new series of Feature articles, celebrating the history of prosthetic heart valve innovation. Other highlights include:
- 5-year real-world outcomes of the INSPIRIS RESILIA valve
- Two billion cycles: INSPIRIS RESILIA valve demonstrates 50 years of mechanical durability
- RESILIA tissue valves: Sustained excellent safety outcomes in patients with aortic stenosis, aortic regurgitation or mixed aortic valve disease
- Congress highlights from DGTHG and STS
Past issues
April 2022
Issue 1
- Haemodynamic change over 5 years following RESILIA tissue valve AVR
- Congress deep dive – Professor Ruggero De Paulis on INDURE registry
- Positive 3-year results for INSIRIS RESILIA valve
- Influence of tissue technology on pannus formation on bioprosthetic heart valves
- Prof. Soo’s review of INSPIRIS RESILA valve
September 2022
Issue 2
- SAVR outcomes in patients under 60 years old
- Congress deep dive – Dr. Joseph Bavaria on a sub-analysis of 5-year COMMENCE data
- Five-year outcomes following bicuspid aortic valve replacement with RESILIA tissue
- INSPIRIS RESILIA valve: A 1 billion cycle in vitro study
- Valves in practice: Prof. Hendrik Treede
November 2022
Issue 3
- INSPIRIS RESILIA valve milestones
- EACTS scientific sessions
- INDURE registry update
- Haemodynamics of Magna Ease and INSPIRIS RESILIA valves
- Mid-term echocardiograph results for INSPIRIS RESILIA
- Comparison of INSPIRIS RESILIA valve with a conventional stented and rapid-deployment valve
- EACTS lunch symposia
- INSPIRIS RESILIA valve in bicuspid aortic valve patients
- Aortic regurgitation in INDURE
- Aortic valve in practice: Interview with Professor Olaf Wendler, the first physician to implant an INSPIRIS RESILA valve
April 2023
Issue 4
- Congress highlights: Professor D’Onofrio on 5-year clinical and haemodynamic outcomes
- Three-year outcomes for the INSPIRIS RESILIA in younger patients
- Haemodynamic performance of INSPIRIS RESILIA in Japanese patients
- Predicted long-term cost savings associated with RESILIA tissue valves
- How close are we to achieving a calcification-resistant bioprosthesis?
- Experience with RESILIA valve: Interview with Professor Vlad Gariboldi
July 2023
Issue 5
- Congress highlights: Dr Beaver presents the COMMENCE trial 7-year data shared at the AATS Meeting in May
- Dr Joseph Bavaria and Prof. Michael Borger share their perspectives on the COMMENCE 7-year data
- Durability of RESILIA tissue valves at 5 years compared with contemporary tissue valves
- Mid-term performance of the INSPIRIS RESILIA valve in Japanese patients
- Mid-term efficacy of the INSPIRIS RESILIA valve in patients under 70 years of age
November 2023
Issue 6
- RESILIA tissue in the mitral position: learn about the features of the MITRIS RESILIA valve and the mid-term outcomes from the COMMENCE mitral clinical trial
- INSPIRIS RESILIA valve performance in the real world, including the longest follow‑up to date
- Cost effectiveness data associated with INSPIRIS RESILIA valve versus mechanical valves
March 2024
Issue 7
- Read about first experiences with the MITRIS RESILIA valve, including learnings from double valve replacements
- Seven-year data from the COMMENCE aortic trial, including a bicuspid aortic valve sub-analysis
- INSPIRIS RESILIA valve performance in the real world
July 2024
Issue 8
- Data on the INSPIRIS RESILIA valve in younger patients presented at the SFCTCV meeting in France
- Analysis of the INSPIRIS RESILIA valve in bicuspid versus tricuspid morphology from the IMPACT and INDURE registries
- Subgroup analysis of the 5-year outcomes for patients with mixed aortic valve disease from the COMMENCE aortic trial
October 2024
Issue 9
- From the beginning: The first implantation of the INSPIRIS RESILIA valve
- The importance of innovation in cardiac surgery
- Looking to the future with RESILIA tissue: Lifetime management and valve-in-valve technology
- Implanting the INSPIRIS RESILIA valve: A spotlight on patients
November 2024
Issue 10
- Highlights from EACTS 2024
- Six-year real-world analysis of the INSPIRIS RESILIA valve clinical outcomes in patients younger and older than 65 years old
- Gender-based analysis of the INSPIRIS RESILIA valve in the IMPACT and INDURE registries
- Five-year real-world outcomes of the INSPIRIS RESILIA valves in patients with chronic kidney disease
- Case studies of MITRIS RESILIA valve implantation
Click here to download the INSPIRIS RESILIA aortic valve Data Compendium
This healthcare professional focused booklet explores the latest clinical studies and publications involving the INSPIRIS RESILIA valve and RESILIA tissue through the review of 24 publications and abstracts.
Each reference has been summarized visually over 1 or 2 slides, for you to save time.
*Clinical data on valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-years in progress.
Beaver T, Bavaria JE, Griffith B et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2024; 168: 781–91.
†RESILIA tissue tested against tissue from commercially-available bovine pericardial valves from Edwards in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg 2015;149:340–5
Refer to device instructions for use for important warnings related to VFit technology. These features have not been observed in clinical studies to establish the safety and effectiveness of the model 11500A for use in valve-in-valve procedures. VFit technology is available on sizes 19–25 mm.
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).